BioSpace News Archive

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab in third-line metastatic colorectal cancer.

Bio-Thera Solutions Inc. will present a poster at the 2024 ASCO Annual Meeting entitled “Phase 1 study of BAT8006, a folate receptor α antibody drug conjugate with strong bystander effect, in subjects with advanced solid tumors,” that highlights clinical data for the potential best-in-class efficacy and safety of BAT8006 as a potential treatment for ovarian cancer patients and other patients with tumors that express Folate Receptor-alpha.

ImPact Biotech announced additional efficacy and safety data from ENLIGHTED, its ongoing pivotal Phase 3 clinical trial evaluating Padeliporfin VTP in patients with low-grade UTUC.

Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria.

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation at the 2024 American Society of Cancer Oncology Annual Meeting being held in Chicago from May 31-June 4, 2024.

GSK plc announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating belantamab mafodotin, in combination with pomalidomide plus dexamethasone, versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.

CatalYm announced positive new follow-up results from its ongoing “GDFATHER” Phase 1/2a trial in an oral presentation at the American Society of Clinical Oncology Annual Meeting 2024 in Chicago.

BioCryst Pharmaceuticals, Inc. announced new real-world evidence showing that patients with hereditary angioedema who have normal C1-inhibitor level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO®.

Precede Biosciences shared two scientific poster presentations from the 2024 American Society of Clinical Oncology Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.